{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"ORR is defined as percentage of participants who achieved a CR or PR out of all the participants treated. Tumor responses were measured and record using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST) v1.1 guidelines. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.","groups":[{"description":"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).","id":"OG000","title":"LY3499446 Monotherapy + Combination Drugs Phase 2"},{"description":"Docetaxel IV infusion.","id":"OG001","title":"Docetaxel Phase 2"}],"populationDescription":"Zero participants were analyzed due to early termination of study.","reportingStatus":"POSTED","timeFrame":"Baseline through Measured Progressive Disease","title":"Phase 2: Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) in Colorectal Cancer (CRC) Cohorts and Other Tumors Cohort","type":"PRIMARY"}